UgenTec, a Belgian company developing independent PCR analysis software based on artificial intelligence and machine learning, closed a €2.15 million ($2.31 million) post-seed funding round.

The new funds come from current investors but also from a credit facility of BNP Paribas Fortis. The additional funding follows the strong growth in sales & operations during 2016.

“We are excited that our investors express enduring trust in our business and want to invest in order for faster growth,” said Tom Martens, managing director at UgenTec. He also stated that the new capital will be used for the development of new requirements and to expand sales internationally.

UgenTec is currently developing the world’s first intelligent platform to automate PCR data interpretation independent of the device or assay.